Matt Hoffman

Whether comprised of a nurse anesthetist or anesthesiologist assistant, patients undergoing surgery experienced no significant differences in mortality, length of stay, or inpatient costs.

Tofacitinib was evaluated for the expansion of its indication based on data from 3 clinical trials.

Submissions can include products in any stage of development and will be accepted from June 1 to September 30, 2018. The selections will be announced in November.

Poison Control Centers get roughly 200 calls each week related to children and adolescents under the age of 19 being exposed to medications intended for attention-deficit hyperactivity disorder.

Specifically, the first 4 days of the capsules were packaged with 4 non-hormonal placebo capsules in place of their active counterparts.

Delaying gratification in youth may not be as much of a predictor of later life outcomes, contradictory to previous findings.

According to BioMarin, the therapy is expected to be available in June 2018, with marketing beginning immediately.

The FDA’s decision was made based on a retrospective analysis of 1000 radiograph images that were used to evaluate the independent enactment of the OsteoDetect AI algorithm.

Since its original approval in 2008, more than 8 million patients worldwide have received a XIENCE stent, according to Abbott.

Treated with Medtronic’s Symplicity Spyral renal denervation system, those patients experienced no major adverse safety events at 6 months.

Avinger stated that it plans to incorporate this next generation version of the device into its ongoing clinical trial program, INSIGHT, an FDA Investigation Device Exemption study.

The bill will now head to President Donald Trump for final approval, which will likely be the case, as the president has repeatedly supported the potential new law, most recently in his 2018 State of the Union address.

The lifetime risks for a female with only amyloidosis are 8.4% for a 90-year-old and 29.3% for a 65-year-old, but persons younger than 85 years with mild cognitive impairment, amyloidosis, and neurodegeneration have lifetime risks of AD dementia greater than 50%.

The agency’s decision was made based on data from 2 phase 3 clinical trials—ADAPT-1 and ADAPT-2—which tested the safety and efficacy of avatrombopag in 435 patients.

The therapy is a first of the histamine H3 receptor-antagonist/inverse agonist class—working by enhancing the histaminergic neurons in the brain.

Between 3 and 9 months post-discharge, 36.9% of those aged 76+ years were prescribed an opioid, with a 5.0% incidence of long-term opioid use.

All told, 41.5% of those receiving dupilumab every 2 weeks and 38% of those receiving it every 4 weeks achieved an Eczema Area and Severity Index score ≥75%, compared with 8% of those receiving placebo.

David Walling, PhD, discussed the biggest misconceptions about patients with schizophrenia, including the high rate of suicide among this population.

David Walling, PhD, discussed the results from a pharmacokinetic and safety study that evaluated aripiprazole lauroxil NanoCrystal Dispersion therapy initiation.

The 14-point guideline included recommendations for initial psychiatric evaluation and assessment, treatment goals and plans, use of multiple medications, and for patients that are pregnant or breastfeeding.

The use of the popular smartphone application Pokémon GO—and possibly similar games—could have potential therapeutic benefits for those with mental illness.

According to survey data released by the American Psychiatric Association, almost 50% of Americans believe the crisis is impacting their peers, and 31% know someone addicted to opioids.

If approved, therapy would be the first of its kind to target Glx for the treatment of bipolar depression.

The mean level of anxiety has increased 5 points since 2017 on a 100-point scale, with Baby Boomers reporting a 7-point jump over the last year.

Women who continued using antipsychotic medications during pregnancy had an absolute risk of 4.2% to 12% of developing gestational diabetes.

Patients that had their medication selection guided by the GeneSight pharmacogenomic testing were 50% more likely to achieve remission and 30% more likely to achieve treatment response.

John Greden, MD, discussed the challenges physicians face in diagnosing, identifying, and treating depression, and the populations that are still severely underserved.

Darrell Kirch, MD, spoke at the APA’s annual meeting about the impact physician burnout has had and what can be done to address it and to improve clinician well-being.

Mayumi Okuda, MD, talked about what clinicians need to be doing and aware of in the identification of patients experiencing intimate partner violence.

The use of electroconvulsive therapy in patients with bipolar depression resulted in higher remission rates while showing similar response rates to unipolar major depression.